SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Virios Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

92829J104

(CUSIP Number)

September 20, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 $\square Rule 13d-1(b)$ $\square Rule 13d-1(c)$ $\square Rule 13d-1(d)$

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	CUSIP No. 92829J104	13G	Page 2 of 9 Pages
1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE	PERSONS (ENTITIES ONLY)	
	Ionic Ventures, LLC		
2.	CHECK THE APPROPRIATE BOX IF A ME	MBER OF A GROUP	
	(see instructions)		
	(a) \square		
3.	(b) SEC USE ONLY		
5.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZAT	ION	
	California, United States		
	5. SOLE VOTING POWER		
	0		
NUMBER O	6. SHARED VOTING POWER		
SHARES			
BENEFICIAL	LY 1,830,000		
OWNED BY	Y 7. SOLE DISPOSITIVE POWER		
EACH REPORTIN			
PERSON WI	TU 0		
TERSON WI	8. SHARED DISPOSITIVE POWER		
	1,830,000		
9.	AGGREGATE AMOUNT BENEFICIALLY	DWNED BY EACH REPORTING PERSON	
	1,830,000		
10.	CHECK IF THE AGGREGATE AMOUNT IN	I ROW (9) FXCLUDES CERTAIN SHARES	
10.	(see instructions) \Box	(KOW ()) EACEODES CERTINIT SILINES	
11.	PERCENT OF CLASS REPRESENTED BY	AMOUNT IN ROW (9)	
	9.98%		
12.	TYPE OF REPORTING PERSON (see instruc	tions)	
	00		

1.	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Brendan O'Neil
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(see instructions)
	(a)
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
	5. SOLE VOTING POWER
NUMBER C	0
SHARES	6. SHARED VOTING POWER
BENEFICIAL	LY .
OWNED B	v1,830,000
EACH	7. SOLE DISPOSITIVE POWER
REPORTIN	G
PERSON WI	
	8. SHARED DISPOSITIVE POWER
	1,830,000
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1.830.000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
	(see instructions)
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.98%
12.	TYPE OF REPORTING PERSON (see instructions)
	IN

1.	NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Keith Coulston
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(see instructions)
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
	5. SOLE VOTING POWER
	. 0
NUMBER C SHARES	6. SHARED VOTING POWER
BENEFICIAL	I V
OWNED B	V 1,830,000
EACH	7. SOLE DISPOSITIVE POWER
REPORTING	a di seconda di second
PERSON WI	
	8. SHARED DISPOSITIVE POWER
	1,830,000
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,830,000
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
	(see instructions)
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.98%
12.	TYPE OF REPORTING PERSON (see instructions)
	IN

Item 1(a). Name of Issuer:

Virios Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

The Issuer's principal executive offices are located at 44 Milton Avenue, Alpharetta, Georgia, 30009.

Item 2(a). Names of Persons Filing:

This statement is filed by:

(i) Ionic Ventures LLC, a California limited liability company ("Ionic");

(ii) Brendan O'Neil ("Mr. O'Neil"); and

(iii) Keith Coulston ("Mr. Coulston").

The foregoing persons are hereinafter sometimes collectively referred to as the ("<u>Reporting Persons</u>"). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256 San Francisco, CA 94123.

Item 2(c). Citizenship:

Ionic is a limited liability company organized under the laws of California. Each of Mr. O'Neil and Mr. Coulston is a citizen of the United States.

Item 2(d). Title of Class of Securities:

The title of the class of securities to which this statement relates is Common Stock, par value \$0.0001 per share.

Item 2(e). CUSIP Number:

92829J104

Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on 18,330,390 shares of Common Stock outstanding as reported in the Issuer's Prospectus Supplement on Form 424B4, filed with the U.S. Securities and Exchange Commission on September 21, 2022.

As of the date hereof, Ionic is the beneficial owner of 1,830,000 shares of Common Stock (the <u>Shares</u>"). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its managers, Mr. O'Neil and Mr. Coulston. Mr. O'Neil and Mr. Coulston, as managers of Ionic, have shared power to vote and/or dispose of the Shares beneficially owned by Ionic. Neither Mr. O'Neil nor Mr. Coulston directly owns any Common Stock of the Issuer. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O'Neil and Mr. Coulston may be deemed to beneficially own the Shares beneficially owned by Ionic.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

CUSIP No. 92829J104

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP No. 92829J104

13G

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 21, 2022

IONIC VENTURES, LLC

/s/ Keith Coulston Name: Keith Coulston Title: Partner

/s/ Brendan O'Neil Brendan O'Neil

/s/ Keith Coulston Keith Coulston

EXHIBIT 1

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

Date: September 21, 2022

IONIC VENTURES, LLC

/s/ Keith Coulston Name: Keith Coulston Title: Partner

/s/ Brendan O'Neil Brendan O'Neil

/s/ Keith Coulston

Keith Coulston